BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
23 May 2017 - 9:00PM
Business Wire
BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a
clinical-stage biotechnology company developing and commercializing
products addressing degenerative diseases, today announced that
BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be
featured in two presentations at the 16th National Life Sciences
and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017
as part of the Regenerative and Cell Therapies track. The
conference is being held at the David InterContinental in Tel Aviv,
Israel, May 23-25, 2017.
Presentations will be held at 12:15 p.m. and 3:45 p.m. IDT in
Hall B of the InterContinental, and will highlight both the
company’s technology and business model. Jim Knight, BioTime, Inc.
Senior Vice President and Head of Corporate Development, will
discuss the evolution of the BioTime group of companies during one
of the presentations. A second presentation will focus on
cell-based transplantation therapy in AMD patients. Each
presentation will be followed by a panel discussion. More
information about the conference program and presentations can be
found here.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what the company believes to be the world’s premier collection of
pluripotent cell assets. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are
capable of becoming any of the cell types in the human body.
Pluripotent cells have potential application in many areas of
medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for
which there presently are no cures. Unlike pharmaceuticals that
require a molecular target, therapeutic strategies based on the use
of pluripotent cells are generally aimed at regenerating or
replacing affected cells and tissues, and therefore may have
broader applicability than pharmaceutical products. BioTime also
has significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which
BioTime founded and which, until recently, were majority-owned
consolidated subsidiaries of BioTime.
BioTime common stock is traded on the NYSE MKT and TASE
under the symbol BTX. For more information, please
visit www.biotimeinc.com or connect with the company on
Twitter, LinkedIn, Facebook, YouTube, and Google+.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170523005380/en/
Investor Contact:EVC Group, Inc.Michael Polyviou/Doug Sherk,
646-445-4800mpolyviou@evcgroup.com; dsherk@evcgroup.comorMedia
Contact:JQA Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024